1214342-99-0Relevant academic research and scientific papers
Efficient Suzuki-Miyaura mono-arylation of symmetrical diiodo(hetero)arenes
Sapegin, Alexander,Krasavin, Mikhail
supporting information, p. 1948 - 1951 (2018/04/16)
A reliable protocol for converting 1,4-diiodo-2,3,5,6-tetrafluorobenzene into 1-(hetero)aryl-4-iodo-2,3,5,6-tetrafluorobenzene derivatives has been lacking in the literature. We have identified optimal conditions to achieve this conversion in good yields and have minimized formation of the bis-coupling product. The newly identified protocol involving the use of a syringe pump has been extended to other symmetrical diiodo(hetero)arenes.
Cushing's syndrome: Development of highly potent and selective CYP11B1 inhibitors of the (pyridylmethyl)pyridine type
Emmerich, Juliette,Hu, Qingzhong,Hanke, Nina,Hartmann, Rolf W.
, p. 6022 - 6032 (2013/09/02)
Potent and selective CYP11B1 inhibitors could be promising therapeutics for the treatment of Cushing's syndrome. Optimization of Ref 1 (5-((1H-imidazol-1- yl)methyl)-2-phenylpyridine) led to compound 44 (5-((5-methylpyridin-3-yl) methyl)-2-phenylpyridine) with a 50-fold improved IC50 value of 2 nM toward human CYP11B1 and an enhanced inhibition of the rat enzyme (IC 50 = 2440 nM) compared to Ref 1 (IC50 > 10000 nM). Furthermore, selectivities over CYP11B2, CYP17, and CYP19 were observed, as well as satisfying metabolic stability not only in human and rat plasma but also in liver S9 fraction. Investigation of cytotoxicity and inhibition of hepatic CYP2A6 and CYP3A4 showed that 44 fulfills first safety criteria and can be considered for further in vivo evaluation in rats.
